6results about How to "Ability to inhibit migration" patented technology

This invention discloses the application of a branched-chain amino acid (BCAA) restricted diet in the preparation of drugs for treating liver metastases of tumors. Through mouse model experiments, this invention found that restricting the intake of BCAAs (valine, isoleucine, and leucine) in the diet, or using the SCD1 inhibitor A939572, can significantly inhibit liver metastases of tumors, especially pancreatic cancer liver metastases. Experimental results show that a BCAA restricted diet or SCD1 inhibitor can reduce the number and volume of liver metastases and inhibit their growth. This invention also reveals its mechanism of action: BCAA restriction reduces the propionylation modification of SREBP1, downregulates the transcriptional expression of its target gene SCD1, and thus reduces lipid synthesis, thereby exerting an anti-tumor liver metastasis effect. This invention provides a novel dietary intervention strategy and drug target for the treatment of liver metastases of tumors.

The invention discloses application of an acer palmatum 'Jinling Huangfeng' extract in preparation of a medicine for preventing and treating breast cancer, and belongs to the technical field of natural product extraction. The invention further discloses an extraction method of the acer palmatum 'Jinling Huangfeng' extract and a separation method of active ingredients of the acer palmatum 'Jinling Huangfeng' extract. Scratch repair experiments directly prove that the acer palmatum 'Jinling Huangfeng' extract can significantly inhibit the migration ability of highly metastatic breast cancer cells MDA-MB-231. The separation method of the active components of the acer palmatum 'Jinling Huangfeng' extract is closely linked with anti-breast cancer metastasis activity screening, so that the experimental process has definite pharmacological guidance quality, the efficiency and success rate of finding the active components are greatly improved, and a high-value candidate resource is provided for developing anti-metastasis drugs.

This invention belongs to the field of pharmaceutical technology, specifically relating to a novel use of berberine hydrochloride and a pharmaceutical composition. Berberine hydrochloride has the structure shown below, and it significantly inhibits the expression of HMGB3 in triple-negative breast cancer cells, significantly inhibits the proliferation, colony formation, invasion, and migration of triple-negative breast cancer cells, and promotes apoptosis in triple-negative breast cancer cells. Therefore, berberine hydrochloride can be used to prepare drugs for the prevention and / or treatment of triple-negative breast cancer. Furthermore, berberine hydrochloride can enhance the drug sensitivity of cisplatin; the combined use of berberine hydrochloride and cisplatin has a strong synergistic effect in the treatment of triple-negative breast cancer, providing more treatment options for clinical treatment of triple-negative breast cancer.

This invention provides the application of costunolide in the preparation of a drug for preventing posterior capsule opacification. Costunolide effectively reduces posterior capsule opacification after extracapsular lens extraction (ECLE) and exhibits significant anti-inflammatory and anti-fibrotic effects in both in vitro and in vivo models. Mechanistic studies have identified matrix metalloproteinase 8 (MMP8) as a key downstream effector of costunolide, confirming that costunolide inhibits MMP8 expression, thereby blocking the transformation of lens epithelial cells (LECs) into mesenchymal cells and subsequent fibrotic processes. This lays a solid foundation for developing targeted therapies for posterior cataract, a common surgical complication.

The invention discloses an application of a novel peptide UPCP in preparation of a medicine for treating and / or preventing psoriasis. Belongs to the technical field of biological medicine. The application discloses the treatment effect of the novel peptide UPCP on psoriasis for the first time, and researches find that the novel peptide UPCP can effectively relieve symptoms of a psoriasis model induced by LSP, TNF alpha and M2 in an in-vitro cell experiment, significantly down-regulate the expression level of psoriasis cell markers, significantly reduce the transcriptional level of psoriasis-related inflammatory factors, and improve the psoriasis treatment effect. The condition of excessive proliferation of HaCaT cells is effectively reduced. In in-vivo experiments, psoriasis symptoms such as skin desquamation, hyperplasia, erythema, thickening and splenomegaly of an imiquimod-induced psoriasis mouse model can be effectively relieved, the effect of treating psoriasis is achieved, and a new theoretical basis and intervention means are provided for clinical treatment of psoriasis.

The invention relates to the technical field of biology, in particular to application of a CDH18 gene serving as a target spot to screening of drugs for preventing or treating cervical cancer, the drugs take the CDH18 gene as the target spot, expression of the CDH18 gene is inhibited or silenced, the proliferation and migration capacity of cervical cancer cells can be enhanced by regulating and controlling a Wnt pathway through overexpression of the CDH18 gene, and the drugs for preventing or treating cervical cancer can be used for preventing or treating cervical cancer. The down-regulation of the CDH18 gene inhibits the expression of beta-catenin, the knock-down of the CDH18 gene can inhibit the proliferation and migration ability of cervical cancer cells by regulating and controlling a Wnt signal pathway, the kaempferide has a certain potential anti-tumor activity effect in the cervical cancer cells, the kaempferide can induce the apoptosis of SiHa and HeLa cells of cervical cancer, and the kaempferide can inhibit the proliferation and migration ability of the cervical cancer cells. Experiments show that the kaempferide inhibits the expression level of Wnt signal pathway related molecules by reducing the expression level of CDH18, further promotes apoptosis of cervical cancer cells and inhibits proliferation and migration of the cervical cancer cells.